EUVIMEDEUVIMED entdecken
Crossref

Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation

Raena Kaur, Duncan Purtill, Julian Cooney, Paul Cannell, Matthew Wright, Tandy-Sue Copeland, Matthew McGuire, Peter Boan iD

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Raena Kaur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Fiona Stanley Hospital and PathWest Laboratory Medicine WA, Murdoch, Australia. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Cytopenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) is a common cause of morbidity after allogeneic haematopoietic cell transplantation (alloHCT). Pre‐emptive therapy (PET) with valganciclovir (VGC) is associated with haematological toxicity.

Methods

We included alloHCT patients from 2018 to 2021 where letermovir (LTV) was used for CMV PET because of cytopenias.

Results

Ten patients were included. Six received VGC prior to LTV. VGC was commenced at median d42, given for median 40 days. LTV was commenced at median d90, given for median 54 days. At commencement of antiviral, CMV viral load was higher for VGC at 3.7 log 10 IU/mL, compared to LTV at 2.9 log 10 IU/mL. Viral load reduction occurred at 0.18 log 10 IU/mL per week for VGC, compared to 0.17 log 10 IU/mL per week for LTV. There was no clinically significant CMV viremia after stopping LTV. Cytopenias improved on LTV.

Conclusion

LTV was effective in controlling CMV viremia when it was given at a lower starting CMV viral load and later post alloHCT than VGC. Further study is required of LTV as upfront PET following alloHCT. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationCytopeniaHumansCytomegalovirusAntiviral AgentsViremiaTreatment OutcomeValganciclovirAcetatesQuinazolines

Stichwörter der Autor:innen

cytomegalovirusletermovirpre-emptive therapypre-emptive treatmentstem cell transplant

Substanzen

Antiviral AgentsValganciclovirletermovirAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Haematology, Fiona Stanley Hospital and PathWest Laboratory Medicine WA, Murdoch, Australia.
  • Department of Pharmacy, Fiona Stanley Hospital, Murdoch, Australia.
  • Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Australia.
  • Department of Microbiology, PathWest Laboratory Medicine WA, Murdoch, Australia.

ORCID-Profile: Peter Boan

Zitieren

APA

Kaur, R., Purtill, D., Cooney, J., Cannell, P., Wright, M., Copeland, T. S., McGuire, M., & Boan, P. (2023). Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. https://doi.org/10.1111/tid.14147

Vancouver

Kaur R, Purtill D, Cooney J, Cannell P, Wright M, Copeland TS, et al. Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. 2023. doi:10.1111/tid.14147

BibTeX
@article{Kaur2023,
  author = {Kaur, Raena and Purtill, Duncan and Cooney, Julian and Cannell, Paul and Wright, Matthew and Copeland, Tandy-Sue and McGuire, Matthew and Boan, Peter},
  title = {Letermovir for pre‐emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14147}
}
Kostenlos starten →